Compounds > bismuth
Page last updated: 2024-08-26

bismuth and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

bismuth has been researched along with 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brechbiel, MW; Dobbs, D; Gansow, OA; Junghans, RP; Mirzadeh, S; Raubitschek, AA; Waldmann, TA1
Axworthy, DB; Brechbiel, MW; Carrasquillo, JA; Garmestani, K; Goldman, CK; Mallett, RW; Theodore, LJ; Waldmann, TA; Yao, Z; Zhang, M; Zhang, Z1
Bruchertseifer, F; Huber, T; Kessler, H; Knör, S; Magdolen, V; Morgenstern, A; Sato, S; Schmitt, M; Seidl, C; Senekowitsch-Schmidtke, R1
Blechert, B; Bruchertseifer, F; Essler, M; Gärtner, FC; Morgenstern, A; Neff, F; Seidl, C; Senekowitsch-Schmidtke, R1
Bendall, SC; Fantl, WJ; Han, G; Nolan, GP; Spitzer, MH1

Other Studies

5 other study(ies) available for bismuth and 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

ArticleYear
Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Cancer research, 1993, Dec-01, Volume: 53, Issue:23

    Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Bismuth; Half-Life; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mice, Nude; Radioimmunotherapy; Radioisotopes; Receptors, Interleukin-2; Tissue Distribution

1993
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
    Blood, 2002, Jul-01, Volume: 100, Issue:1

    Topics: Alpha Particles; Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biotin; Bismuth; Heterocyclic Compounds, 1-Ring; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Neoplasms, Experimental; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Interleukin-2; Streptavidin; Survival Rate; Treatment Outcome

2002
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:1

    Topics: Alpha Particles; Animals; Bismuth; Cell Line, Tumor; Dimerization; Drug Discovery; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Ligands; Mice; Neoplasm Metastasis; Ovarian Neoplasms; Peptides; Polygeline; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Solubility; Substrate Specificity; Tissue Distribution

2008
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:4

    Topics: Actinium; Animals; Bismuth; Cell Line, Tumor; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kidney; Mice; Organometallic Compounds; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Treatment Outcome; Xenograft Model Antitumor Assays

2012
Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry.
    Nature protocols, 2018, Volume: 13, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Bismuth; Chelating Agents; Flow Cytometry; Heterocyclic Compounds, 1-Ring; Humans; Immunoassay; Immunoconjugates; Immunoglobulin G; Indium; Isotopes; Jurkat Cells; Metals; Mice, Inbred C57BL; Palladium; Yttrium

2018